California-based molecular diagnostics company MiraDx has added Prostox Standard to its portfolio – marking another US launch in the company’s cancer testing portfolio. The diagnostic assay is ...
LOS ANGELES--(BUSINESS WIRE)--MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new ...
PROSTOX test predicts urinary side effects in prostate cancer patients using microRNAs to assess genetic risk factors. The test identifies high-risk patients, who are 10 to 12 times more likely to ...
The test, called PROSTOX, is the first of its kind to use microRNAs to predict toxicity from cancer therapy. It could help prevent the burden of long-term complications by identifying patients most at ...
New Publication Shows PROSTOX™ ultra Test Delivers Significant Health System Cost Savings and Quality-of-Life Gains for Prostate Cancer Patients Undergoing Radiation Therapy MiraDx, a molecular ...
The test, called PROSTOX, is the first of its kind to use microRNAs to predict toxicity from cancer therapy. It could help prevent the burden of long-term complications by identifying patients most at ...
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results